Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966693 | 0.84 | ALDH1A1 (0.74) | HSD11B1ALDH1A1HPGDPOLBHTT | |
| SCHEMBL8947294 | 0.82 | MAPK1 (0.61) | HSD11B1ALDH1A1HPGDPOLBHTT | |
| SCHEMBL8947261 | 0.81 | ALDH1A1 (0.75) | HSD11B1ALDH1A1HPGDPOLBHTT | |
| SCHEMBL1520494 | 0.81 | HSD11B1 (0.58) | HSD11B1ALDH1A1HPGDPOLBHTT | |
| SCHEMBL1775515 | 0.81 | HSD11B1 (0.56) | HSD11B1ALDH1A1HPGDPOLBHTT | |
| SCHEMBL5966689 | 0.81 | TRPV1 (0.59) | HSD11B1ALDH1A1HPGDPOLBHTT | |
| SCHEMBL1154434 | 0.79 | ALDH1A1 (0.62) | HSD11B1ALDH1A1HPGDPOLBHTT | |
| SCHEMBL8947310 | 0.78 | TRPV1 (0.63) | HSD11B1ALDH1A1HPGDPOLBHTT | |
| SCHEMBL8947249 | 0.77 | MEN1 (0.59) | HSD11B1ALDH1A1HPGDPOLBHTT | |
| SCHEMBL8947331 | 0.77 | ALDH1A1 (0.84) | HSD11B1ALDH1A1HPGDPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | HSD11B1 598/4885ALDH1A1 394/4885HPGD 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.